Methoxy polyethylene glycol-epoetin beta

Aviceda Therapeutics raised $207.5M for AVD-104's phase 2/3 SIGLEC trial in geographic atrophy, aiming to improve treatment efficacy. Other biotech financings include Orbis Medicines' €90M Series A, Alebund Pharmaceutical's RMB 550M round, XyloCor Therapeutics' $67.5M Series B, and PrimeGene's RMB 300M second round for various drug developments.

Alebund Pharmaceuticals secured RMB 550 million in Series C financing to advance renal disease therapies, including AP301 and AP306, and expand Mircera®'s market in China. The company focuses on innovative treatments for chronic kidney disease and related conditions, with a diversified pipeline and a new production site in Yangzhou.

Alebund Pharmaceuticals secured RMB 550 million in Series C financing to advance renal disease therapies, including AP301 and AP306 development, and Mircera® expansion in China. The funding supports global clinical programs and commercial activities, aiming to address chronic kidney disease's growing health impact.

Alebund Pharmaceuticals secured RMB 550 million in Series C financing to advance renal disease therapies, including AP301 and AP306, and expand Mircera® in China. The funding supports NDA in China, global studies, and commercial growth, addressing chronic kidney disease's rising global health challenge.

Alebund Pharmaceuticals secured RMB 550 million in Series C financing to advance renal disease therapies, including AP301 and AP306, and expand Mircera® in China. The funding supports NDA in China, global studies, and commercial growth, addressing chronic kidney disease's rising global health challenge.

Alebund Pharmaceuticals closed a RMB 550 million Series C financing to advance renal disease therapies, including AP301 and AP306 development, and Mircera® expansion in China. The company focuses on innovative treatments for chronic kidney diseases and related conditions, with a diversified pipeline and a dedicated commercial team in China.

Dr Gink Yang explores precision medicine in ophthalmology, focusing on Fuchs' endothelial corneal dystrophy (FECD) diagnosis via single-cell RNA sequencing. This technique offers detailed insights into disease progression, aiding in treatment decisions between corneal transplant and Descemet stripping without endothelial keratoplasty (DWEK). A clinical trial led by Associate Professor Elaine Chong and Dr Elsie Chan evaluates DWEK suitability, while Dr Yang's work garners international attention, aiming to bring targeted treatments to FECD patients.